Reviewers scrutinize Jardiance's CV efficacy data

FDA is asking an advisory committee to vote on whether data from a cardiovascular outcomes trial (CVOT) show diabetes drug Jardiance empagliflozin does not result in an unacceptable increase

Read the full 290 word article

User Sign In